Technology
Health
Biotechnology
Coherus BioSciences
$14.139876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$14.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.19 (-1.33%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell CHRS and other stocks, options, ETFs, and crypto commission-free!
About
Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Read More Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Employees
232
Headquarters
Redwood City, California
Founded
2010
Market Cap
978.09M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
700.13K
High Today
$14.40
Low Today
$13.40
Open Price
$14.28
Volume
215.69K
52 Week High
$20.66
52 Week Low
$8.32
Collections
Technology
Health
Biotechnology
Medical
Therapy
2014 IPO
US
North America
News
MarketBeatMar 7
Stock Price, News, & Analysis for Coherus Biosciences
Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic...
Price Paid on Robinhood
12% Lower
Right Now
52 Week Low
$8.32
Average Price Paid
$15.98
52 Week High
$20.66
Earnings
-$1.09
-$0.73
-$0.36
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, After Hours